ID   RPMI-8866
AC   CVCL_1668
SY   RPMI 8866; RPMI8866; Roswell Park Memorial Institute 8866; R8866; 8866
DR   BTO; BTO:0004206
DR   CLO; CLO_0008875
DR   CLO; CLO_0009858
DR   CLDB; cl4186
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   Cell_Model_Passport; SIDM00482
DR   ChEMBL-Cells; CHEMBL3308323
DR   ChEMBL-Targets; CHEMBL2366341
DR   Cosmic; 910544
DR   Cosmic-CLP; 910544
DR   DepMap; ACH-002302
DR   ECACC; 95041316
DR   EGA; EGAS00001000978
DR   GDSC; 910544
DR   GEO; GSM1670391
DR   IARC_TP53; 21292
DR   LINCS_LDP; LCL-1113
DR   PharmacoDB; RPMI8866_1329_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1668
DR   Wikidata; Q54951275
RX   DOI=10.1007/978-1-4757-1647-4_11;
RX   PubMed=4169031;
RX   PubMed=6967232;
RX   PubMed=17254797;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   HLA typing: A*02,03; B*07 (PubMed=6967232).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0.14%; East Asian, North=0%; East Asian, South=0%; South Asian=3.24%; European, North=67.29%; European, South=29.33% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): Cosmic-CLP; ECACC; PubMed=17254797
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 10,14
ST   D16S539: 11
ST   D18S51: 12,15
ST   D21S11: 27,29
ST   D3S1358: 15,16
ST   D5S818: 12
ST   D7S820: 11,12
ST   D8S1179: 12,14
ST   FGA: 22,23
ST   TH01: 9.3 (Cosmic-CLP; ECACC)
ST   TH01: 10 (PubMed=17254797)
ST   TPOX: 8,11
ST   vWA: 14,16
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   51Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 34
//
RX   DOI=10.1007/978-1-4757-1647-4_11;
RA   Moore G.E.;
RT   "Cell lines from humans with hematopoietic malignancies.";
RL   (In) Human tumor cells in vitro; Fogh J. (eds.); pp.299-331; Springer; New York (1975).
//
RX   PubMed=4169031; DOI=10.4049/jimmunol.99.5.839;
RA   Finegold I., Fahey J.L., Granger H.;
RT   "Synthesis of immunoglobulins by human cell lines in tissue culture.";
RL   J. Immunol. 99:839-848(1967).
//
RX   PubMed=6967232; DOI=10.1007/BF01538802;
RA   Gladstone P., Pious D.A.;
RT   "Identification of a trans-acting function regulation HLA-DR
RT   expression in a DR-negative B cell variant.";
RL   Somatic Cell Genet. 6:285-298(1980).
//
RX   PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001;
RA   Azari S., Ahmadi N., Tehrani M.J., Shokri F.;
RT   "Profiling and authentication of human cell lines using short tandem
RT   repeat (STR) loci: report from the National Cell Bank of Iran.";
RL   Biologicals 35:195-202(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//